Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease.
Aged
Aged, 80 and over
Coronary Artery Disease
/ blood
Female
Heart Diseases
/ mortality
Heart Failure
/ epidemiology
Hospitalization
/ statistics & numerical data
Humans
Inflammation
/ blood
Leukocyte Count
Lymphocyte Count
Male
Middle Aged
Myocardial Infarction
/ epidemiology
Neutrophils
Percutaneous Coronary Intervention
Platelet Count
Prognosis
Proportional Hazards Models
Stroke
/ epidemiology
coronary artery disease
inflammation
percutaneous coronary intervention
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
13
10
2019
revised:
28
03
2020
accepted:
02
04
2020
pubmed:
16
4
2020
medline:
24
3
2021
entrez:
16
4
2020
Statut:
ppublish
Résumé
This study examines the predictive value of a novel systemic immune-inflammation index (SII, platelet × neutrophil/lymphocyte ratio) in coronary artery disease (CAD) patients. A total of 5602 CAD patients who had undergone a percutaneous coronary intervention (PCI) were enrolled. They were divided into two groups by baseline SII score (high SII vs low SII) to analyse the relationship between SII groups and the long-term outcome. The primary outcomes were major cardiovascular events (MACE) which includes nonfatal myocardial infarction (MI), nonfatal stroke and cardiac death. Secondary outcomes included a composite of MACE and hospitalization for congestive heart failure. An optimal SII cut-off point of 694.3 × 10 SII had a better prediction of major cardiovascular events than traditional risk factors in CAD patients after coronary intervention.
Sections du résumé
BACKGROUND
BACKGROUND
This study examines the predictive value of a novel systemic immune-inflammation index (SII, platelet × neutrophil/lymphocyte ratio) in coronary artery disease (CAD) patients.
METHODS
METHODS
A total of 5602 CAD patients who had undergone a percutaneous coronary intervention (PCI) were enrolled. They were divided into two groups by baseline SII score (high SII vs low SII) to analyse the relationship between SII groups and the long-term outcome. The primary outcomes were major cardiovascular events (MACE) which includes nonfatal myocardial infarction (MI), nonfatal stroke and cardiac death. Secondary outcomes included a composite of MACE and hospitalization for congestive heart failure.
RESULTS
RESULTS
An optimal SII cut-off point of 694.3 × 10
CONCLUSIONS
CONCLUSIONS
SII had a better prediction of major cardiovascular events than traditional risk factors in CAD patients after coronary intervention.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13230Subventions
Organisme : Taiwan Association for integration of Cardiology and surgery
ID : TAICS-107-2-Y2
Informations de copyright
© 2020 Stichting European Society for Clinical Investigation Journal Foundation.
Références
Yusuf S, Reddy S, Ôunpuu S, Anand S. Global burden of cardiovascular diseases. Circulation. 2001;104:2746-2753.
Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007;27:15-26.
Oh TJ, Ahn CH, Kim BR, et al. Circulating sortilin level as a potential biomarker for coronary atherosclerosis and diabetes mellitus. Cardiovasc Diabetol. 2017;16:92.
Yu P, Zhao J, Jiang H, et al. Neural cell adhesion molecule-1 may be a new biomarker of coronary artery disease. Int J Cardiol. 2018;257:238-242.
Dick SA, Epelman S. Chronic heart failure and inflammation: what do we really know? Circ Res. 2016;119:159-176.
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2012;2:98-98.
Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860.
Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
Goff David C, Lloyd-Jones Donald M, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014;129:S49-S73.
Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611-619.
Arbel Y, Finkelstein A, Halkin A, et al. Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis. 2012;225:456-460.
Kurtul A, Murat SN, Yarlioglues M, et al. Association of platelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in patients with acute coronary syndromes. Am J Cardiol. 2014;114:972-978.
Hu B, Yang X-R, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20:6212-6222.
Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J Cancer. 2018;9:3295-3302.
Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8:75381-75388.
Seo M, Yamada T, Morita T, et al. P589Prognostic value of systemic immune-inflammation index in patients with chronic heart failure. Eur Heart J. 2018;39:ehy564.P589.
Leu HB, Yin WH, Tseng WK, et al. Identification of new biosignatures for clinical outcomes in stable coronary artery disease - the study protocol and initial observations of a prospective follow-up study in Taiwan. BMC Cardiovasc Disord. 2017;17:42.
Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest. 2010;40:35-53.
Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2937-2944.
Levey AS, Coresh J, Balk E, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147.
Chen SC, Lin CP, Hsu HC, et al. Serum bilirubin improves the risk predictions of cardiovascular and total death in diabetic patients. Clin Chim Acta. 2019;488:1-6.
Hansson Göran K, Libby P, Schönbeck U, Yan Z-Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281-291.
Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol. 2014;9:73-102.
Doring Y, Soehnlein O, Weber C. Neutrophil extracellular traps in atherosclerosis and atherothrombosis. Circ Res. 2017;120:736-743.
Erkol A, Oduncu V, Turan B, et al. Neutrophil to lymphocyte ratio in acute ST-segment elevation myocardial infarction. Am J Med Sci. 2014;348:37-42.
Ates AH, Aytemir K, Kocyigit D, et al. Association of neutrophil-to-lymphocyte ratio with the severity and morphology of coronary atherosclerotic plaques detected by multidetector computerized tomography. Acta Cardiol Sin. 2016;32:676-683.
Haft JI. Role of blood platelets in coronary artery disease. Am J Cardiol. 1979;43:1197-1206.
Handin RI. Platelets and coronary artery disease. N Engl J Med. 1996;334:1126-1127.
Pasalic L, Wang SS, Chen VM. Platelets as biomarkers of coronary artery disease. Semin Thromb Hemost. 2016;42:223-233.
Yuksel M, Yildiz A, Oylumlu M, et al. The association between platelet/lymphocyte ratio and coronary artery disease severity. Anatol J Cardiol. 2015;15:640-647.
Dick Sarah A, Epelman S. Chronic heart failure and inflammation. Circ Res. 2016;119:159-176.
Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E. Monocytes in coronary artery disease and atherosclerosis: where are we now? J Am Coll Cardiol. 2013;62:1541-1551.
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-1131.
Doll JA, Hellkamp AS, Goyal A, Sutton NR, Peterson ED, Wang TY. Treatment, outcomes, and adherence to medication regimens among dual medicare-medicaid-eligible adults with myocardial infarction. JAMA Cardiol. 2016;1:787-794.
Kulik A, Shrank WH, Levin R, Choudhry NK. Adherence to statin therapy in elderly patients after hospitalization for coronary revascularization. Am J Cardiol. 2011;107:1409-1414.
Iqbal J, Serruys PW. Revascularization strategies for patients with stable coronary artery disease. J Intern Med. 2014;276:336-351.
Ohtsuka T, Hamada M, Hiasa G, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;37:412-417.